Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer
Shots:
- The companies collaborated to evaluate Mirati's adagrasib (KRASG12C inhibitor) + Sanofi's SAR442720 (SHP2 inhibitor) in P-I/II dose-escalation & expansion study in patients with previously-treated NSCLC & KRASG12C mutations
- Adagrasib & SAR442720 demonstrated an anti-tumor activity in pre-clinical models & both have complementary MoA
- Sanofi will be responsible for sponsoring & operating the P-I/II study & both companies will share the cost of the study. Additionally- Adagrasib is being evaluated as monothx. and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors- including NSCLC- colorectal cancer & pancreatic cancer
| Ref: PR Newswire | Image: Trading View
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
